Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Gemini Space Station Inc (GEMI) Price & Performance

Crispr Therapeutics AGTrade
Gemini Space Station IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Gemini Space Station Inc — how do they compare? Crispr Therapeutics AG trades at $53.82 (market cap $5.23B), while Gemini Space Station Inc trades at $4.06 (market cap $512.05M). The key difference: Crispr Therapeutics AG is far larger — about 10.2× Gemini Space Station Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.

CRSPGEMI
Market Cap
$5.23B$512.05M
Sector
HealthTechnology
52-Week High
$76.78$32.52
52-Week Low
$44.34$3.90
Enterprise Value
$3.65B$502.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Gemini Space Station Inc

GEMI trades at $4.04, down 1.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $582.81M in 2025 on revenue of $179.57M, with negative gross and net income margins. Recent news includes a $100M investment from Winklevoss Capital and multiple class-action lawsuits alleging securities law violations.

The outlook remains challenging due to persistent losses and legal overhangs, though analyst consensus suggests a potential upside to $6.33. Key risks include ongoing unprofitability, competitive pressures in financial services, and regulatory scrutiny. Investment opportunity hinges on the company's ability to achieve profitability and navigate legal challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

Read more on GEMI